Start Here
Your guided introduction to retatrutide research. Follow the sections below to build a solid understanding of the science, evidence, and clinical landscape surrounding this investigational triple receptor agonist.
What Is Retatrutide?
Retatrutide (LY3437943) is an investigational peptide developed by Eli Lilly that simultaneously activates three metabolic hormone receptors: GIP, GLP-1, and glucagon. This triple-agonist mechanism sets it apart from existing incretin-based therapies and has shown significant weight-loss and metabolic outcomes in clinical trials.
What Is Retatrutide?
Comprehensive overview of the molecule, its development, and why it matters
Understand the Science
Dive deeper into how retatrutide works at the molecular and physiological level.
Clinical Evidence
Review the clinical trial data, outcomes, and safety profile.
Compare With Other Treatments
See how retatrutide stacks up against other incretin-based therapies in head-to-head comparisons.
Reference Tools
Quick-access tools and reference materials for ongoing research.
Stay Updated
Follow the latest developments and contribute to the knowledge base.